Purpose: Cyclins, and their associated cyclin dependent kinases, regulate progression of the cell cycle through the G1 phase and into the S-phase during the DNA replication process. Cyclin E regulation is an important event in cell proliferation. Despite its importance, abnormalities of these genes and their protein products have yet to be found in lits asoociation with lung cancer.
INTRODUCTION
Lung cancer is one of the leading cancer deaths throughout the world. Despite major advances in cancer treatment, during the past two decades, lung cancer carries a very poor prognosis, and the overall 5-year survival rate has remained less than 15%
(1).
Although tumor, node and metastasis stage is the most significant prognostic parameter to be considered, the variability of survival within the staging groups requires additional parameters, which influences the outcome, independent of stage factors.
The molecular alterations in lung cancer have been extensively studied (2) . They consist mainly of inactivating the mutations of tumor suppressor genes, activating mutations of oncogenes, loss of heterozygosity, and amplification of chromosomal regions. Recent progress in the study of the molecular biology of cancer has contributed to a better understanding of its molecular pathogenesis, including that of lung cancer. Cell proliferation is regulated by many factors.
Recent studies have shown that cyclins and cyclin-dependent protein kinase (cdk) complexes have important roles, during the cell cycle progression (3, 4) . Regulatory mechanisms include variations in cyclin abundance, phosphorylation of the kinase sub-unit that may yield either positive or negative effects, or the actions of cyclin-kinase inhibitory proteins. The complex formed by cyclin D1 and cdk4 governs the G1 progression, while cyclin E and cyclin A in connection with cdk2, regulates the entry to and progression through the S phase (5) . In this investigation, they analyzed the prognostic value of cyclin A, cyclin D1, cdk2, and cdk4 in patients with squamous cell carcinoma of the lung. Cyclins D and E are relatively recently described proteins that are implicated in the pathogenesis of non-small cell lung carcinomas (NSCLCs). Cyclins and their associated cyclin-dependent kinases regulate progression of the cell cycle, through the G1 phase and into the S-phase of the DNA replication process (4) . Overexpression of cyclin D1 and cyclin E has been demonstrated to shorten the G1 phase of the cell cycle (6) .
Studies examining the use of immunohistochemical staining for cyclins, as a potential prognostic marker, are rare.
Overexpression of cyclin D1 and cyclin E has been reported in several tumors, such as colorectal, head and neck, esophageal, breast, uterus, hepatocellular, in addition to lung carcinoma, melanomas, and sarcoma (7).
In the present study, we have used immunohistochemical techniques to analyze the overexpression of cyclins in human NSCLCs to elucidate the potential role in tumor development.
The relationship to various clinicopathological factors was then determined. Monoclonal antibodies against human cyclin E protein (NCI-cyclin E, clone 13Ae) and human cyclin D1 protein (NCL-cyclin D1-GM, clone P2D11F11) were purchased from Novocastra (Newcastle, UK). Anti-cyclin E antibody was diluted at 1:50, and anti-cyclin D1 antibody was diluted at 1:20.
MATERIALS AND METHODS

1) Patients and tissue samples
The slides were washed, incubated with biotinylated goat anti-mouse immunoglobulin G antibody, and incubated with avidin-biotin-peroxidase complex for 10 minutes, using a streptavidin-biotin complex peroxidase kit (Large Volume DAKO LSAB kit; Dako, Glostrup, Denmark). Afterwards, the chromogen 3, 3'-diaminobenzidine tetrahydrochloride was applied for 10 minutes and weak counterstaining was carried out with Mayer's hematoxylin.
The number of tumor cells with nuclear immunopositivity was graded on a scale of: 0, less than 1%; 1, 1 to 30%; 2, 30 to 60%; and 3, more than 60%. Histologic subtype, stage, and age, gender were correlated with grade of immunohistochemical staining.
3) Statistical analysis
Statistical associations between cyclin A, B1, D1, D3, and E immunoreactivity and various clinicopathologic factors were determined, using the χ 2 test for categorical variables. A p-value of less than 0.05 was considered statistically significant.
RESULTS
The patients ranged in age from 41 to 85 years, at the time of diagnosis, with a mean age of 63.1 years. tumor stroma and accompanying inflammatory cell were negative. The overexpression of staining was estimated over score 2. The positive immunoreactivity was observed in 51 cases (50%) for cyclin A, 33 cases (32%) for cyclin B1, 83 cases (81%) for cyclin D1, 19 cases (18%) for cyclin D3, and 11 cases (11%) for cyclin E (Fig. 1 ). The expression of cyclin A and D1 represented more than 50% all of NSCLCs.
However, that of cyclin B1 was frequently observed in squamous cell carcinoma (30/68, 44%), compared to that of adenocarcinoma (2/25, 8%), which was not significant for statistical analysis. Cyclin E positivity was frequently found in large cell carcinoma (2/8, 25%), compared to that of squamous cell carcinoma (8/68, 11%) and adenocarcinoma (1/25, 4%).
There were no significant differences of the expression of Table 2 .
DISCUSSION AND CONCLUSION
Lung cancer is a major cause of mortality, worldwide. To further improve the survival rate in this group of patients, their prognostic classification, which is based on tumor biology, will be crucial. Such classification might help clinicians to make the right management decisions for each subset of patients. There were some studies that have evaluated the clinical significance of cyclin D1 and E expression in NSCLCs.
Overexpression and/or amplification of cyclin D1 has been reported in a large variety of human cancers, including those of the esophagus, head and neck, lung, liver, and breast (4) and is reported to be of prognostic importance in patients with most of these tumor types (15, 16) . These studies have suggested that overexpression of cyclin D1 shortens the G1 phase and accelerates cell growth, thus, positively contributing to oncogenesis. Cyclin E overexpression has also been observed in (19) .
In summary, we have demonstrated the high cyclin E expression represented correlation with lymph node metastasis and was an unfavorable prognostic factor. Cyclin E might be a potential neo prognostic factor of NSCLCs.
